ED STATES PATENT AND TRADEMAR Atty Dkt. 2801-36 In re Patent Application of C# 1621 FANTO et al Group Art Unit: Serial No. 09/533,381 Examiner: Barts Filed: March 26, 2001 Date: December 19, 2001 S MANDARHARMACEUTICAL COMPOSITIONS FOR THE 2-AMINOTETRALINÈ Title: PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY AND/OR **AUTOIMMUNE PATHOLOGIES** Assistant Commissioner for Patents Washington, DC 20231 Sir: RESPONSE/AMENDMENT/LETTER This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon. Fees are attached as calculated below: Total effective claims after amendment 9 minus highest number \$ 0.00 previously paid for 20 (at least 20) =Х \$ 18.00 Independent claims after amendment minus highest number 0.00 previously paid for (at least 3) = 0 \$ 84.00 9 Х If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper) 0.00 Petition is hereby made to extend the current due date so as to cover the filing date of this 0.00 paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months) Terminal disclaimer enclosed, add \$ 110.00 0.00 First/second submission after Final Rejection pursuant to 37 C.F.R. 1.129(a) (\$740.00) 0.00 Please enter the previously unentered . filed Submission attached Subtotal 0.00If "small entity," then enter half (1/2) of subtotal and subtract 0.00 Applicant claims "small entity" status. Statement filed herewith Rule 56 Information Disclosure Statement Filing Fee (\$180.00) 0.00 Assignment Recording Fee (\$40.00) 0.00 Other: 0.00 TOTAL FEE ENCLOSED \$ 0.00 asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

The Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, in the fee(s) filed, or


1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

ARC:Isp

NIXON & VANDERHYE P.C.

By Atty: Arthur R. Crawford, Reg. No. 25,327

Signature:



In re Patent Application of

FANTO et al

Serial No. 09/533,381

Filed: March 26, 2001

Atty. Ref.: 2801-36

Group: 1621

Examiner: Barts

For: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE

PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY

AND/OR AUTOIMMUNE PATHOLOGIES

Assistant Commissioner for Patents Washington, DC 20231

Sir:

December 19, 200 CENTER 1600/2900

RESPONSE

Responsive to the Official Action dated December 7, 2001, Paper No. 4, and requirement for restriction presented in it, applicants elect the subject matter of Group II, namely, claims 9, 12 and 15 drawn to a method of preventing or treating septic shock. Specific embodiments of the invention are disclosed in the data given on pages 40-47 of the specification.

Responsive to item 4 of the Official Action, the elected single disclosed species is (R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride (ST 1275) which is disclosed in the specification at page 6, line 12, and otherwise identified throughout the specification and data as ST 1275.

This response is made with traverse. The compounds disclosed in the present application are effective in counteracting the aetiopathogenetic role of inflammatory cytokines (see page 1, first paragraph). Inflammatory cytokines are responsible for septic shock and inflammatory and/or autoimmune pathologies (see page 1, last paragraph to page 2, first paragraph).

Examination on the merits is awaited taking into account the Information Disclosure Statement filed March 26, 2001.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Arthur R/Crawford Reg. No. 25,327

ARC:lsp

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100